

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 19/167, A61K 31/70	A1	(11) International Publication Number: WO 94/07905 (43) International Publication Date: 14 April 1994 (14.04.94)
(21) International Application Number: PCT/US93/08269 (22) International Filing Date: 2 September 1993 (02.09.93) (30) Priority data: 07/954,180 30 September 1992 (30.09.92) US (71) Applicant: MERRELL DOW PHARMACEUTICALS INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (72) Inventors: PEET, Norton, P. ; 8028 Chestershire Drive, Cincinnati, OH 45241 (US). BORCHERDING, David, R. ; 12137 Brisben Drive, Cincinnati, OH 45249 (US). LENTZ, Nelsen, L. ; 8266 Rollingwood Way, West Chester, OH 45069 (US). WEINTRAUB, Philip, M. ; 8145 Maxfield Lane, Cincinnati, OH 45215 (US).	(74) Agent: SAYLES, Michael, J.; Marion Merrell Dow Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (81) Designated States: AU, CA, FI, HU, JP, KR, NO, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: 2-SUBSTITUTED ADENOSINES WITH A-2 RECEPTOR AFFINITY (57) Abstract Adenosine analogues which act selectively at adenosine receptors and which act in general as adenosine agonists are disclosed. From <i>in vitro</i> studies it is known that specific physiological effects can be distinguished as a result of this selectivity and that adenosine receptor activity <i>in vitro</i> correlates with adenosine receptor activity <i>in vivo</i> . Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which will enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

-1-

5

2-SUBSTITUTED ADENOSINES WITH A-2 RECEPTOR AFFINITY

10

FIELD OF THE INVENTION

The present invention relates to a group of compounds which are adenosine analogues and which act selectively at adenosine receptors.

15

BACKGROUND OF THE INVENTION

The profound hypotensive, sedative, antispasmodic, and vasodilatory actions of adenosine were first recognized over 50 years ago. Subsequently, the number of biological roles proposed for adenosine have increased considerably. The adenosine receptors appear linked in many cells to adenylyate cyclase. A variety of adenosine analogues have been introduced in recent years for the study of these receptor functions. Alkylxanthines, such as caffeine and theophylline, are the best known antagonists of adenosine receptors.

Adenosine perhaps represents a general regulatory substance, since no particular cell type or tissue appears uniquely responsible for its formation. In this regard, adenosine is unlike various endocrine hormones. Nor is there any evidence for storage and release of adenosine from nerve or other cells. Thus, adenosine is unlike various neurotransmitter substances.

35

Adenosine might be compared as a physiological regulator to the prostaglandins. In both cases the enzymes

-2-

involved in the metabolic formation are ubiquitous and appear to be responsive to alterations in the physiological state of the cell. Receptors for adenosine, like those for prostaglandins, are proving to be very widespread.

5 Finally, both prostaglandins and adenosine appear to be involved with the regulation of functions involving calcium ions. Prostaglandins, of course, derive from membrane precursors, while adenosine derives from cytosolic precursors.

10 Although adenosine can affect a variety of physiological functions, particular attention has been directed over the years toward actions which might lead to clinical applications. Preeminent have been the cardiovascular effects of adenosine which lead to vasodilation
15 and hypotension but which also lead to cardiac depression. The antilipolytic, antithrombotic and antispasmodic actions of adenosine have also received some attention. Adenosine stimulates steroidogenesis in adrenal cells, again probably via activation of adenylate cyclase. Adenosine has
20 inhibitory effects on neurotransmission and on spontaneous activity of central neurons. Finally, the bronchoconstrictor action of adenosine and its antagonism by xanthines represents an important area of research.

25 It has now been recognized that there are not one but at least two classes of extracellular receptors involved in the action of adenosine. One of these has a high affinity for adenosine and, at least in some cells, couples to adenylate cyclase in an inhibitory manner. These have been
30 termed by some as the A-1 receptors. The other class of receptors has a lower affinity for adenosine and in many cell types couples to adenylate cyclase in a stimulatory manner. These have been termed the A-2 receptors.

35 Characterization of the adenosine receptors has now been possible with a variety of structural analogues. Adenosine analogues resistant to metabolism or uptake


-3-

mechanisms have become available. These are particularly valuable, since their apparent potencies will be less affected by metabolic removal from the effector system. The adenosine analogues exhibit differing rank orders of potencies at A-1 and A-2 adenosine receptors, providing a simple method of categorizing a physiological response with respect to the nature of the adenosine receptor. The blockade of adenosine receptors (antagonism) provides another method of categorizing a response with respect to the involvement of adenosine receptors. It should be noted that the development of potent antagonists specific to A-1 or A-2 adenosine receptors would represent a major breakthrough in this research field and in the preparation of adenosine receptor selective pharmacological agents having specific physiological effects in animals.

SUMMARY OF THE INVENTION

The present invention relates to compounds of Formula

I:



FORMULA I

wherein R_1 and R_2 are each independently hydrogen or C_1 - C_4 alkyl, R_3 is C_1 - C_4 alkyl, C_1 - C_4 alkoxy or halogen, and n is an integer from 0 to 3.

DETAILED DESCRIPTION OF THE INVENTION

As used herein the term " C_1 - C_4 alkyl" refers to a saturated straight or branched chain hydrocarbon radical of one to four carbon atoms. Included within the scope of this term are methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl and the like. The term " C_1 - C_4 alkoxy" refers to an

-4-

alkyloxy radical made up of an oxygen radical bearing a saturated straight or branched chain hydrocarbyl radical of one to four carbon atoms and specifically includes methoxy, ethoxy, propyloxy, isopropyloxy, n-butyloxy, iso-butyloxy, sec-butyloxy, tertiary butyloxy and the like. The term "halogen" refers to fluorine, chlorine, bromine, or iodine.

Stereoisomerism is possible with the present compounds and the chemical structure as presented above is considered as encompassing all of the possible stereoisomers and racemic mixtures of such stereoisomers. More specifically, when R₁ and R₂ are defined as in Formula I and are nonequivalent, the respective carbon atom is chiral and optical isomerism is possible.

15

As examples of compounds of the present invention are the following:

1. (R)-2-[(phenylisopropyl)amino]adenosine
2. (S)-2-[(phenylisopropyl)amino]adenosine
- 20 3. (R)-2-[(1-Phenylpropyl)amino]adenosine
4. (S)-2-[(1-Phenylpropyl)amino]adenosine


The general synthetic process for compounds of Formula I is set forth in Scheme A. All the substituents, unless otherwise indicated, are previously defined. The reagents and starting materials for use in this process are readily available to one of ordinary skill in the art.

Scheme A

30

In Scheme A, step a, 2'- and 3'-hydroxyl groups of 2-chloroadenosine (1) are protected as the acetonide defined by structure (2). Following the general procedure of Hampton [J. Am. Chem. Soc., 83, 3640 (1961)], an equivalent of 2-chloroadenosine is combined with approximately 10 equivalents of 2,2-dimethoxypropane and approximately 5 equivalents of *p*-toluenesulfonic acid in an appropriate

-5-



solvent such as N,N-dimethylformamide. After stirring at room temperature for approximately 20 hours the product is isolated and purified by techniques well-known to one skilled in the art. For example, an excess of a suitable aqueous base such as saturated sodium bicarbonate is added and the solvent is removed under vacuum. The residue is extracted with a suitable organic solvent such as chloroform, dried over magnesium sulfate, filtered and concentrated under vacuum. The crude product can be purified by flash chromatography or recrystallization methods to provide the acetonide (2).

In Scheme A, step b, the acetonide (2) is then treated with an appropriately substituted primary amine to provide the secondary amine of structure (3). More specifically,

-6-

the acetonide (2) is combined with a large excess of an appropriately substituted primary amine, such as L-(-)-amphetamine, D-(+)-amphetamine, (R)-1-phenylpropylamine or (S)-1-phenylpropylamine, under an atmosphere of an inert gas such as nitrogen. The mixture is then heated to approximately 130°C with stirring for approximately 3 to 6 hours. After cooling, the product can be isolated and purified by techniques well known to one skilled in the art. For example, the crude mixture can be directly purified by flash chromatography followed by radial chromatography using an appropriate eluent such as 3% to 6% methanol/chloroform to provide the secondary amine (3).

In Scheme A, step c, the secondary amine (3) is then deprotected under acidic conditions to provide the compound of Formula I. More specifically, the secondary amine (3) is treated with an excess of a suitable acid, such as 1M hydrochloric acid and heated to approximately 40°C to 50°C for about 30 minutes. After cooling, the product can be isolated and purified by techniques well-known to one skilled in the art. For example, the reaction is treated with an excess of a suitable weak base, such as saturated aqueous sodium bicarbonate and then extracted with a suitable organic solvent, such as chloroform. The organic extracts are dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The crude residue can then be purified by chromatographic techniques, such as radial chromatography and then treated with ethereal hydrogen chloride to provide the hydrochloride salt of Formula I.

-7-

Therapeutic Utility Of
Selective Adenosine Receptor Agents

The table below shows in more detail the potential therapeutic utility of selective adenosine receptor agents
 5 in accordance with the present invention:

<u>Area</u>	<u>Effect</u>	<u>Receptor Correlate</u>
Cardiovascular	cardiotonic	A-1 antagonism
Cardiovascular	control tachycardia	A-1 agonism
Cardiovascular	increase coronary blood flow	A-2 agonism
Cardiovascular	vasodilation	A-2 (atypical) agonism
Pulmonary	bronchodilation	A-1 antagonism
Pulmonary	mediation of autocoid release from mast cells, basophils	novel adenosine receptor interaction on cell surface
Pulmonary	stimulate respiration; treat paradoxical ventilatory response (infants)	Ado antagonism
Renal	inhibit renin release	A-1 agonism
Central Nervous System	aid in opiate withdrawal	Ado agonism
Central Nervous System	analgesic	A-1 agonism
Central Nervous System	anticonvulsant	A-1 agonism
Central Nervous System	antidepressant	A-1 agonism
Central Nervous System	antipsychotic	Ado agonism
Central Nervous System	anxiolytic	agonism
Central Nervous System	inhibition of self-mutilation behavior (Lesch-Nyhan syndrome)	Ado agonism
Central Nervous System	sedative	A-2 agonism

35 In the cardiovascular, pulmonary and renal system targets, designed compounds which are identified by receptor binding studies can be evaluated in functional *in vivo* tests

-8-

which are directly indicative of the human physiological response. A good description of the pharmacology and functional significance of purin receptors is presented by M. Williams in Ann. Rev. Pharmacol. Toxicol., 27, 31

5 (1987). In a section entitled "Therapeutic Targeting of Adenosine Receptor Modulators" it is stated that "adenosine agonists may be effective as antihypertensive agents, in the treatment of opiate withdrawal, as modulators of immune competence and renin release, as antipsychotics and as
10 hypnotics. Conversely, antagonists may be useful as central stimulants, inotropics, cardiotonics, antistress agents, antiasthmatics, and in the treatment of respiratory disorders." The smorgasbord of activities displayed by adenosine receptor agents underscores their great potential
15 utility for therapy and the need for central agents.

Adenosine exerts its various biological effects via action on cell-surface receptors. These adenosine receptors are of two types, A-1 and A-2. The A-1 receptors are
20 operationally defined as those receptors at which several ⁶C-N substituted adenosine analogs such as R-phenylisopropyladenosine (R-PIA) and cycloadenosine (CHA) are more potent than 2-chloroadenosine and N-5'-ethylcarboxamido-adenosine (NECA). At A-2 receptors the order of potency is
25 instead NECA>2-chloroadenosine>R-PIA>CHA.

As illustrated in the table above, adenosine receptors govern a variety of physiological functions. The two major classes of adenosine receptors have already been defined.
30 These are the A-1 adenosine receptor, which is inhibitory of adenylate cyclase, and the A-2 adenosine receptor, which is stimulatory to adenylate cyclase. The A-1 receptor has a higher affinity for adenosine and adenosine analogs than the A-2 receptor. The physiological effects of adenosine
35 and adenosine analogs are complicated by the fact that non-selective adenosine receptor agents first bind the rather ubiquitous low-affinity A-2 receptors, then as the dose is

-9-

increased, the high-affinity A-2 receptors are bound, and finally, at much higher doses, the very high-affinity A-1 adenosine receptors are bound. (See J. W. Daly, et al., *Subclasses of Adenosine Receptors in the Central Nervous System: Interaction with Caffeine and Related Methylxanthines*, Cellular and Molecular Neurobiology, 3, (1), 69-80 (1983).)

In general, the physiological effects of adenosine are mediated by either the stimulation or the inhibition of adenylate cyclase. Activation of adenylate cyclase increases the intracellular concentration of cyclic AMP, which, in general, is recognized as an intracellular second messenger. The effects of adenosine analogs can therefore be measured by either the ability to increase or the ability to antagonize the increase in the cyclic AMP in cultured cell lines. Two important cell lines in this regard are VA 13 (WI-38 VA 13 2RA), SV-40 transformed WI 38 human fetal lung fibroblasts, which are known to carry the A-2 subtype of adenosine receptor, and fat cells, which are known to carry the A-1 subtype of adenosine receptor. (See R.F. Bruns, *Adenosine Antagonism by Purines, Pteridines and Benzopteridines in Human Fibroblasts*, Chemical Pharmacology, 30, 325-33 (1981).)

It is well-known from *in vitro* studies that the carboxylic acid congener of 8-phenyl-1,3-dipropylxanthine (XCC) is adenosine receptor nonselective, with a K_i at the A-1 receptor in rat brain membranes of $58 \pm 3 \text{ nM}$ and a K_i at the A-2 receptor of the rat brain slice assay of $34 \pm 13 \text{ nM}$. The amino congener of 8-phenyl-1,3-dipropylxanthine (XAC), on the other hand, has a 40-fold higher affinity for the A-1 adenosine receptor, with a K_i of $1.2 \pm 0.5 \text{ nM}$, as compared with a K_i at the A-2 receptor of $49 \pm 17 \text{ nM}$. In addition, XAC is much more potent in antagonizing the effects of adenosine analogs on heart rate than on blood pressure. Since it is generally known that the adenosine analog-induced effects on the heart seem to be mediated via A-1

-10-

receptors and those on blood pressure via A-2 receptors, the selectivity of XAC under *in vivo* conditions suggests that adenosine receptor activity *in vitro* correlates with adenosine receptor activity *in vivo* and that specific physiological effects can be distinguished as a result of this selectivity. (See B.B. Fredholm, K.A. Jacobsen, B. Jonzon, K.L. Kirk, Y.O. Li, and J.W. Daly, *Evidence That a Novel 8-Phenyl-Substituted Xanthine Derivative is a Cardiosensitive Adenosine Receptor Antagonist In Vivo*, Journal of Cardiovascular Pharmacology, 9, 396-400, (1987), and also K.A. Jacobsen, K.L. Kirk, J.W. Daly, B. Jonzon, Y.O. Li, and B.B. Fredholm, *Novel 8-Phenyl-Substituted Xanthine Derivative Is Selective Antagonist At Adenosine Receptors In Vivo*, Acta Physiol. Scand., 341-42 (1985).)

It is also known that adenosine produces a marked decrease in blood pressure. This blood pressure reduction is probably dependent upon an A-2 receptor-mediated decrease in peripheral resistance. Adenosine analogs are also able to decrease heart rate. This effect is probably mediated via adenosine receptors of the A-1 subtype.

Thus, it is readily apparent that the pharmacological administration of the adenosine receptor selective adenosine analogs disclosed herein will result in selective binding to either the A-2 or the A-1 receptor, which will, in turn, selectively result in either a decrease in blood pressure or a decrease in heart rate, for example, thereby decoupling these physiological effects *in vivo*. The selection of such adenosine receptor selective agents can be determined by the methods described in further detail below.

Test For Affinity For Brain Adenosine A-2 Receptors

The test described below was used to determine the potency of test compounds to compete with the ligand [³H]-5'-N-ethyl-carboxamidoadenosine (NECA) for the adenosine A-2 receptors prepared from animal brain membranes. (See

-11-

also R.R. Bruns, G.H. Lu, and T.A. Pugsley, *Characterization of the A-2 Adenosine Receptor Labeled by [3H]NECA in Rat Striatal Membranes, Mol. Pharmacol.*, 29, 331-346 (1986).) Young male rats (C-D strain), obtained from Charles River, are killed by decapitation and the brains are removed. Membranes for ligand binding are isolated from rat brain striatum. The tissue is homogenized in 20 vol ice-cold 50 mM Tris-HCl buffer (pH 7.7) using a polytron (setting for 6 to 20 seconds). The homogenate is centrifuged at 50,000 x g for 10 minutes at 4°C. The pellet is again homogenized in a polytron in 20 vol of buffer, and centrifuged as before. The pellet is finally resuspended in 40 vol of 50 mM Tris-HCl (pH 7.7) per gram of original wet weight of tissue.

Incubation tubes, in triplicate, receive 100 μ l of [3H]NECA (94 nM in the assay), 100 μ l of 1 μ M cyclohexyladenosine (CHA), 100 μ l of 100 mM MgCl₂, 100 μ l of 1 IU/ml adenosine deaminase, 100 μ l of test compounds at various concentrations over the range of 10⁻¹⁰ M to 10⁻⁴ M diluted with assay buffer (50 mM Tris-HCl, pH 7.7) and 0.2 μ l of membrane suspension (5 mg wet weight), in a final volume of 1 ml of 50 mM Tris-HCl, pH 7.7. Incubations are carried out at 25°C for 60 minutes. Each tube is filtered through GF/B glass fiber filters using a vacuum. The filters are rinsed two times with 5 ml of the ice-cold buffer. The membranes on the filters are transferred to scintillation vials to which 8 ml of Omnifluor with 5% Protosol is added. The filters are counted by liquid scintillation spectrometry.

30

Specific binding of [3H]NECA is measured as the excess over blanks run in the presence of 100 μ M 2-chloroadenosine. Total membrane-bound radioactivity is about 2.5% of that added to the test tubes. Since this condition limits total binding to less than 10% of the radioactivity, the concentration of free ligand does not change appreciably during the binding assay. Specific binding to membranes is

-12-

about 50% of the total bound. Protein content of the membrane suspension is determined by the method of O.H. Lowry, N.J. Rosebrough, A.L. Farr and R.J. Randall, *Protein Measurements With Folin Phenol Reagent*, J. Biol. Chem., 193, 5 265-275. (1951).

Displacement of [³H]NECA binding of 15% or more by a test compound is indicative of affinity for the adenosine A-2 site. The molar concentration of a compound which 10 causes 50% inhibition of the binding of ligand is the IC₅₀. A value in the range of 100-1000 nM would indicate a highly potent compound.

Test For Affinity For Brain

15 Adenosine A-1 Receptor Binding Sites

The test described below is used to determine the potency of test compounds to compete with the ligand [³H]cycloadenosine for the Adenosine A-1 receptor prepared from rat brain membranes. Male Sprague-Dawley rats are 20 sacrificed by decapitation and the membranes are isolated from whole animal brains. (See R. Goodman, M. Cooper, M. Gavish, and S. Snyder, *Guanine Nucleotide and Cation Regulation of the Binding of [³H] Diethylphenylxanthine to Adenosine A-1 Receptors in Brain Membrane*, Molecular Pharmacology, 21, 329-335 (1982).

25

Membranes are homogenized (using polytron setting 7 for 10 seconds) in 25 volumes of ice-cold 50 mM Tris-HCl buffer, pH 7.7. The homogenate is centrifuged at 19,000 rpm for 10 minutes at 4°C. The pellet is washed by 30 resuspending in 25 volumes of buffer with 2 IU of adenosine deaminase per ml and incubated 30 minutes at 37°C. The homogenate is centrifuged again. The final pellet is resuspended in 25 volumes of ice-cold buffer.

35

The incubation tubes, in triplicate, receive 100 µl of [³H]cyclohexyladenosine, 0.8 nM in the assay, 200 µl of test compounds at various concentrations over the range of

-13-

10-10 M to 10⁻⁶ M diluted with 50 nM Tris-HCl buffer (pH 7.7), 0.2 ml of membrane suspension (8 mg wet weight) and in a final volume of 2 ml with Tris buffer. Incubations are carried out at 25°C for 2 hours and each one is terminated within 10 seconds by filtration through a GF/B glass fiber filter using a vacuum. The membranes on the filters are transferred to scintillation vials. The filters are counted by liquid scintillation spectrometry in 8 ml of Omnifluor containing 5% Protosol.

10

Specific binding of [3H]cycloadenosine is measured as the excess over blanks taken in the presence of 10⁻⁵ M 2-chloroadenosine. Total membrane-bound radioactivity is about 5% of that added to the test tubes. Specific binding to membranes is about 90% of the total bound. Protein content of the membrane suspension is determined by the method of Lowry, et al., *Ibid*, 265.

Displacement of [3H]cyclohexyladenosine binding of 15% or more by a test compound is indicative of affinity for the adenosine binding site.

Adenosine Receptor Binding Affinity Values
Obtained Using The Above Described Test Procedures

The following is a table showing the adenosine receptor binding affinities for several compounds (refer to compound examples on page 5 for cross-reference to compound names) within the scope of the present invention:

Compound	A-1 Receptor K _i	A-2 Receptor K _i	A-1 K _i /A-2 K _i
1.	8.4 x 10 ⁻⁶	3.5 x 10 ⁻⁹	2400
2.	5.8 x 10 ⁻⁶	158 x 10 ⁻⁹	37

The nucleotide guanosine triphosphate (GTP) has been shown to differentially affect the binding of agonists and antagonists to a variety of neurotransmitter receptors. In

-14-

general, guanine nucleotides lower the affinity of agonists for receptors without a concomitant decrease in antagonist affinity. Accordingly, GTP has been shown to decrease the potency of agonists but not antagonists as inhibitors of the binding of the adenosine antagonist [3H]3-diethyl-8-phenylxanthine. In general, GTP greatly reduces the potency of purine agonists, but not antagonists as inhibitors of [3H]phenylisopropyl adenosine binding and is, therefore, an effective agent for distinguishing between agonists and antagonists. (See L.P. Davies, S.C. Chow, J.H. Skerritt, D.J. Brown and G.A.R. Johnston, *Pyrazolo [3,4-d]Pyrimidines as Adenosine Antagonists*, Life Sciences, **34**, 2117-28 (1984). It is understood, in general, that adenosine analogs act as agonists if β -D-ribofuranosyl is present in the molecule at the R₁ position and as an antagonist if R₁ is hydrogen or phenyl.

Pharmaceutical Preparations of the
Adenosine Receptor Selection Adenosine Analogs

The exact amount of the compound or compounds to be employed, i.e., the amount of the subject compound or compounds sufficient to provide the desired effect, depends on various factors such as the compound employed; type of administration; the size, age and species of animal; the route, time and frequency of administration; and, the physiological effect desired. In particular cases, the amount to be administered can be ascertained by conventional range finding techniques.

The compounds are preferably administered in the form of a composition comprising the compound in admixture with a pharmaceutically acceptable carrier, i.e., a carrier which is chemically inert to the active compound and which has no detrimental side effects or toxicity under the conditions of use. Such compositions can contain from about 0.1 μ g or less to 500 mg of the active compound per

-15-

ml of carrier to about 99% by weight of the active compound in combination with a pharmaceutically-acceptable carrier.

The compositions can be in solid forms, such as tablets, capsules, granulations, feed mixes, feed supplements and concentrates, powders, granules or the like; as well as liquid forms such as sterile injectable suspensions, orally administered suspensions or solutions. The pharmaceutically acceptable carriers can include excipients such as surface active dispersing agents, suspending agents, tableting binders, lubricants, flavors and colorants. Suitable excipients are disclosed, for example, in texts such as Remington's Pharmaceutical Manufacturing, 13 Ed., Mack Publishing Co., Easton, Pennsylvania (1965).


The following examples present typical syntheses as described by Scheme A. These examples are understood to be illustrative only and are not intended to limit the scope of the invention in any way. As used in the following examples, the following terms have the meanings indicated: "[α]_D²⁰" refers to the optical rotation of the compound at 20°C using a sodium D light, "g" refers to grams, "mmol" refers to millimoles, "ml" refers to milliliters, "°C" refers to degrees Celsius, "TLC" refers to thin layer chromatography, "mg" refers to milligrams, "μl" refers to microliters, and "δ" refers to parts per million downfield from tetramethylsilane.

30

EXAMPLE 1(R)-2-[(PHENYLISOPROPYL)AMINO]ADENOSINEScheme A, step a

Combine 2-chloroadenosine hemihydrate (0.96 g, 3.09 mmol), 2,2-dimethoxypropane (3.2 g, 30.9 mmol) and p-toluenesulfonic acid (2.93 g, 15.5 mmol) in N,N-dimethylformamide (40 ml). Stir the reaction for 20 hours and then add saturated sodium bicarbonate (70 ml). Concentrate the

-16-



10 reaction under vacuum. Extract the residue with chloroform
(3 x 300 ml). Combine the organic extracts, dry over
anhydrous magnesium sulfate, filter, and concentrate under
vacuum. Purify the residue by radial chromatography (5%
methanol/chloroform, 4mm plate) to provide 1.14 g of the
15 acetonide (2).

Scheme A, step b

Combine the acetonide (2) (444 mg, 0.13 mmol) with L-
(-)-amphetamine (3.4 g) and heat to 130°C for 3.5 hours
20 under nitrogen with stirring. After cooling, purify by
flash chromatography (3% to 4% to 5% methanol/chloroform)
followed by radial chromatography (3% to 4% to 5%
methanol/chloroform, 4mm plate) to provide the secondary
amine (3) (262 mg).

25

Scheme A, step c

Treat the secondary amine (3) (249 mg, 0.57 mmol) with
1M hydrochloric acid (20 ml) and heat the reaction to 50°C
for 30 minutes. Cool the reaction and pour into saturated
30 sodium bicarbonate (200 ml). Extract the reaction with
chloroform (3 x 150 ml). Combine the organic extracts, dry
over anhydrous magnesium sulfate, filter, and concentrate
under vacuum. Purify the residue by radial chromatography
(2% to 4% to 8% to 15% methanol/chloroform, 4mm plate) four
35 times to provide the title compound (105 mg) as the free
base. Treat this with ethereal hydrogen chloride, filter,
and dry the solid under high vacuum over phosphorous

-17-

pentoxide to provide the hydrochloride salt of the Formula I (48 mg), m.p. 153 C dec.; $[\alpha]_D^{20} = -30^\circ$ (c=1.04, H₂O).

5

10

15


20

25

30

35

-18-

EXAMPLE 2(S)-2-[(PHENYLISOPROPYL)AMINO]ADENOSINEScheme A, step a

Combine 2-chloroadenosine hemihydrate (0.96 g, 3.09 mmol), 2,2-dimethoxypropane (3.2 g, 30.9 mmol), and p-toluenesulfonic acid (2.93 g, 15.5 mmol) in N,N-dimethylformamide (40 ml). Stir the reaction for 20 hours and then add saturated sodium bicarbonate (70 ml). Concentrate the reaction under vacuum. Extract the residue with chloroform (3 x 300 ml). Combine the organic extracts, dry over anhydrous magnesium sulfate, filter, and concentrate under vacuum. Purify the residue by radial chromatography (5% methanol/chloroform, 4mm plate) to provide 1.14 g of the acetonide (2).

Scheme A, step b


Combine the acetonide (2) (638 mg, 1.87 mmol) with D-(+)-amphetamine (4.5 g) and heat to 130°C for 5 hours under nitrogen with stirring. After cooling, purify by flash chromatography (3% to 5% to 10% methanol/chloroform) followed by radial chromatography four times (2% to 4% to 6% to 8% to 10% methanol/chloroform, 4mm plate) to provide the secondary amine (3) (0.56 g).

Scheme A, step c

Treat the secondary amine (3) (0.46 g, 1.05 mmol) with 1M hydrochloric acid (40 ml) and heat the reaction to 45°C for 15 minutes. Cool the reaction and pour into saturated

-19-

sodium bicarbonate (300 ml). Extract the reaction with chloroform (3 x 150 ml). Combine the organic extracts, dry over anhydrous magnesium sulfate, filter, and concentrate under vacuum to provide the title compound (0.40 g) as the free base. Treat this with ethereal hydrogen chloride, filter, and dry the solid under high vacuum over phosphorous pentoxide. Recrystallize from 10% methanol/diethyl ether to provide, after drying under high vacuum over phosphorous pentoxide, the hydrochloride salt of the Formula I (184 mg), m.p. 155°C dec.; $[\alpha]_D^{20} = +9.75^\circ$ (c=1.01, H₂O).

EXAMPLE 3(R)-2-[(1-PHENYLPROPYL)AMINO]ADENOSINEScheme A, step b

Combine the acetone (2) (3.4 g, 9.95 mmol) with (R)-1-phenylpropylamine (8.62 g) and heat to reflux for 18 hours. Remove some of the excess amine by distillation. After cooling, purify by flash chromatography (3% methanol in dichloromethane). Triturate the product with diethyl ether to provide the secondary amine (3) (1.38 g); ¹H NMR (CDCl₃) δ 7.41 (1H, s), 7.21-7.34 (4H, m), 7.14-7.22 (1H, m), 5.69 (1H, d), 5.50 (2H, s), 5.25 (1H, d), 5.10 (1H, t), 5.01 (1H, q), 4.90 (1H, q), 4.41 (1H, s), 3.93 (1H, d), 3.80 (1H, d), 1.82 (2H, pent), 1.60 (3H, s), 1.32 (3H, s), 0.94 (3H, t); IR (KBr) 3450-3100, 1633, 1599 cm⁻¹. Anal. Calcd for C₂₂H₂₈N₆O₄: C, 59.99; H, 6.41; N, 19.08. Found: C, 59.99; H, 6.38; N, 18.71.

-20-

Scheme A, step c

Dissolve the above secondary amine (3) with trifluoroacetic acid (20 ml) and treat with water (2 ml).

- 5 After 15 minutes remove the solvent under vacuum. Treat the residue with water/dichloromethane and make the aqueous basic with saturated sodium bicarbonate. Separate the layers, dry the organic phase over anhydrous sodium sulfate, filter, and concentrate under vacuum. Purify the
- 10 resulting solid by flash chromatography (5% to 10% to 15% methanol/dichloromethane) and then recrystallize from acetone to provide the title compound (62 mg); ^1H NMR (DMSO- d_6) δ 7.87 (1H, s), 7.38 (1H, d), 7.27 (2H, t), 7.16 (1H, t), 6.60-6.73 (3H, m, exchangeable), 5.69 (1H, d), 5.31
- 15 (1H, d), 5.02 + 5.12 (2H, brs + d), 4.83 (1H, q), 4.52 (1H, dd), 4.17 (1H, dd), 3.88 (1H, dd), 3.64-3.73 (1H, m), 3.47-3.59 (1H, m), 2.08 (3H, s, Me_2SO), 1.63-1.89 (2H, m), 0.96 (3H, t); IR (KBr) 3423-3290 cm^{-1} .
- Anal. Calcd for $\text{C}_{19}\text{H}_{24}\text{N}_6\text{O}_4 \cdot 1/2\text{C}_3\text{H}_6\text{O}$: C, 57.33; H, 6.34; N, 19.57.
- 20 Found: C, 59.96; H, 6.73; N, 19.92.

25


30

35

-21-

What is claimed is:

1. A compound according to the formula:



wherein R₁ and R₂ are each independently hydrogen or C₁-C₄ alkyl, R₃ is C₁-C₄ alkyl, C₁-C₄ alkoxy or halogen, and n is an integer from 0 to 3.

2. A compound according to claim 1 which is (R)-2-[(phenylisopropyl)amino]adenosine.

- 20 3. A compound according to claim 1 which is (S)-2-[(phenylisopropyl)amino]adenosine.

4. A compound according to claim 1 which is (R)-2-[(1-phenylpropyl)amino]adenosine.

25

30

35

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/08269

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) * According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : C 07 H 19/167, A 61 K 31/70								
II. FIELDS SEARCHED <div style="text-align: center; font-size: small;">Minimum Documentation Searched †</div> <table style="width: 100%; border: none;"> <tr> <td style="width: 30%; border: none;">Classification System</td> <td style="border: none;">Classification Symbols</td> </tr> <tr> <td style="border: none; vertical-align: top;">IPC⁵</td> <td style="border: none; vertical-align: top;">C 07 H, A 61 K</td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched *</div>			Classification System	Classification Symbols	IPC ⁵	C 07 H, A 61 K		
Classification System	Classification Symbols							
IPC ⁵	C 07 H, A 61 K							
III. DOCUMENTS CONSIDERED TO BE RELEVANT* <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; font-size: x-small;">Category *</th> <th style="width: 70%; font-size: x-small;">Citation of Document, ** with indication, where appropriate, of the relevant passages ††</th> <th style="width: 20%; font-size: x-small;">Relevant to Claim No. ‡‡</th> </tr> </thead> <tbody> <tr> <td style="vertical-align: top; text-align: center;">A</td> <td style="vertical-align: top;"> EP, A2, 0 323 807 (CIBA-GEIGY AG) 12 July 1989 (12.07.89), abstract: page 24, lines 37, 38,42. <div style="text-align: center; margin-top: 10px;">----</div> </td> <td style="vertical-align: top; text-align: center;">1-4</td> </tr> </tbody> </table>			Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages ††	Relevant to Claim No. ‡‡	A	EP, A2, 0 323 807 (CIBA-GEIGY AG) 12 July 1989 (12.07.89), abstract: page 24, lines 37, 38,42. <div style="text-align: center; margin-top: 10px;">----</div>	1-4
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages ††	Relevant to Claim No. ‡‡						
A	EP, A2, 0 323 807 (CIBA-GEIGY AG) 12 July 1989 (12.07.89), abstract: page 24, lines 37, 38,42. <div style="text-align: center; margin-top: 10px;">----</div>	1-4						
<div style="font-size: x-small;"> * Special categories of cited documents: †† -A- document defining the general state of the art which is not considered to be of particular relevance -E- earlier document but published on or after the international filing date -L- document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) -O- document referring to an oral disclosure, use, exhibition or other means -P- document published prior to the international filing date but later than the priority date claimed -T- later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention -X- document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step -Y- document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art -Z- document member of the same patent family </div>								
IV. CERTIFICATION <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 10px;">03 November 1993</div> </td> <td style="width: 50%; border: none; vertical-align: top;"> Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">21. 12. 93</div> </td> </tr> <tr> <td style="width: 50%; border: none; vertical-align: top;"> International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div> </td> <td style="width: 50%; border: none; vertical-align: top;"> Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;">SCHNASS e.h.</div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 10px;">03 November 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">21. 12. 93</div>	International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;">SCHNASS e.h.</div>		
Date of the Actual Completion of the International Search <div style="text-align: center; margin-top: 10px;">03 November 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center; margin-top: 10px;">21. 12. 93</div>							
International Searching Authority <div style="text-align: center; margin-top: 10px;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; margin-top: 10px;">SCHNASS e.h.</div>							

ANHANG

zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

ANNEX

to the International Search
Report to the International Patent
Application No.

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/US 93/08269 SAE 79533

In diesem Anhang sind die Mitglieder
der Patentfamilien der in obenge-
nannten internationalen Recherchenbericht
angeführten Patentedokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visée ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

Im Recherchenbericht angeführtes Patentedokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A2 323807	12-07-89	US A 5034381	23-07-91
		AU A1 27767/89	13-07-89
		AU B2 618055	12-12-91
		DK A0 50/89	06-01-89
		DK A 50/89	08-07-89
		EP A3 323807	20-06-90
		FI A0 890028	04-01-89
		FI A 890028	08-07-89
		HU A2 48904	28-07-89
		HU B 202550	28-03-91
		IL A0 88877	15-08-89
		JP A2 1265100	23-10-89
		NO A0 885821	30-12-88
		NO A 885821	10-07-89
		NO B 169843	04-05-92
		NO C 169843	12-08-92
		NZ A 227542	26-03-92
		PT A 89392	08-02-90
		PT B 89392	30-09-93
		DD A5 283402	10-10-90
		ZA A 8900084	30-08-89